Grants

RO1 GM74217-01 Lang Li (PI)                                                   04/01/2005 – 03/31/2010
NIH
Bayesian tools for physiologically-based pharmacokinetics models in drug-drug interaction research.
The aim of this study is to develop computational tools to analyze and predict drug-drug interactions.
Role: Principal Investigator

UO1 GM61373-6 Flockhart (PI)                                                  05/01/2005 – 07/31/2010
NIGMS
Pharmacogenetics Research Network and Knowledge Base
The goals of the project are (1) to determine the variability in the contributions of three genetically polymorphic enzymes (CYP2C9, CYP2D6 and CYP3A) to tamoxifen metabolism in human liver microsomes and in isolated human hepatocytes, (2) to test the hypothesis that CYP2D6, CYP3A or CYP2C9 genetics alter the pharmacokinetics of tamoxifen and its metabolites in a clinical trial in patients being prescribed tamoxifen as an adjuvant, (3) to test the hypothesis that metabolic pharmacogenetics influence the efficacy of tamoxifen through analysis of tamoxifen concentrations and metabolic genotypes in patients enrolled in the NSABP-P1 trial, and (4) to test the hypothesis that genetics alter the toxicity of tamoxifen.
Role: Core-leader (Biostatistics Core)

P50 CA113001 Tim Huang (PI)                                                   09/30/2004 – 09/29/2009
Ohio State University
Interrogating Epigenetic Changes in Cancer Genomes
The goal of this project is to use novel microarray-based and computational approaches for comprehensive profiling of genetic and epigenetic alterations in breast and ovarian cancer.
Role: Core-leader (Biostatistics Core), Co-PI (project 1)

R01 CA85289 Nephew, Kenneth (PI)                                          04/01/2008-03/31/2013
DNA Methylation and Ovarian Cancer
Role: co-I